State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510050, China.
Protein Cell. 2024 Apr 1;15(4):239-260. doi: 10.1093/procel/pwad052.
The profound influence of microbiota in cancer initiation and progression has been under the spotlight for years, leading to numerous researches on cancer microbiome entering clinical evaluation. As promising biomarkers and therapeutic targets, the critical involvement of microbiota in cancer clinical practice has been increasingly appreciated. Here, recent progress in this field is reviewed. We describe the potential of tumor-associated microbiota as effective diagnostic and prognostic biomarkers, respectively. In addition, we highlight the relationship between microbiota and the therapeutic efficacy, toxicity, or side effects of commonly utilized treatments for cancer, including chemotherapy, radiotherapy, and immunotherapy. Given that microbial factors influence the cancer treatment outcome, we further summarize some dominating microbial interventions and discuss the hidden risks of these strategies. This review aims to provide an overview of the applications and advancements of microbes in cancer clinical relevance.
多年来，微生物组在癌症发生和进展中的深远影响一直备受关注，促使许多癌症微生物组的研究进入临床评估。作为有前途的生物标志物和治疗靶点，微生物组在癌症临床实践中的关键作用越来越受到重视。在这里，我们综述了该领域的最新进展。我们分别描述了肿瘤相关微生物组作为有效诊断和预后生物标志物的潜力。此外，我们强调了微生物组与癌症常用治疗方法（包括化疗、放疗和免疫治疗）的疗效、毒性或副作用之间的关系。鉴于微生物因素影响癌症治疗结果，我们进一步总结了一些主要的微生物干预措施，并讨论了这些策略的潜在风险。本综述旨在概述微生物在癌症临床相关性中的应用和进展。
